Showing results (521-530 of 715) with videos related to
Sort By:
Pageof 72
The Lancet. Rheumatology|January 17, 2024
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard A Furie, Eric F Morand, Ian N Bruce, et al.Neuro-Oncology|July 14, 2011
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pumpAdam M Sonabend, R Morgan Stuart, Jonathan Yun, et al.Molecular Cancer Therapeutics|December 13, 2002
CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cellsJung-Taek Yoon, Alexander F Palazzo, Danhua Xiao, et al.Lupus Science & Medicine|March 29, 2022
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteriaRonald van Vollenhoven, Anca D Askanase, Andrew S Bomback, et al.Neurosurgery|April 3, 2008
Identification of A2B5+CD133- tumor-initiating cells in adult human gliomasAlfred T Ogden, Allen E Waziri, Richard A Lochhead, et al.Magnetic Resonance Imaging|October 17, 2022
Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRIMarta Tibiletti, James A Eaden, Josephine H Naish, et al.Journal of Clinical Medicine|October 18, 2018
Drug-Induced Interstitial Lung Disease: A Systematic ReviewSarah Skeoch, Nicholas Weatherley, Andrew J Swift, et al.Genome Medicine|May 20, 2021
Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor markerAndrew X Chen, Robyn D Gartrell, Junfei Zhao, et al.Journal of Neuro-Oncology|February 18, 2015
Outcomes of gamma knife radiosurgery, bi-modality & tri-modality treatment regimens for patients with one or multiple brain metastases: the Columbia University Medical Center experienceTony J C Wang, Shumaila Saad, Yasir H Qureshi, et al.Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.Pageof 72